Investor Alert

Market Pulse Archives

Feb. 26, 2020, 5:22 p.m. EST

Gilead announces more trials for drug aimed at COVID-19, stock up 4%

Watchlist Relevance

Want to see how this story relates to your watchlist?

Just add items to create a watchlist now:

  • X
    Gilead Sciences Inc. (GILD)

or Cancel Already have a watchlist? Log In

By Claudia Assis


Shares of Gilead Sciences Inc. /zigman2/quotes/210293917/composite GILD +3.33% rose nearly 4% in the extended session Wednesday after the pharma company said it had started two clinical studies to gauge the safety and efficacy of its remdesivir drug in adults diagnosed with COVID-19. Beginning in March, the studies will enroll about 1,000 patients at medical centers primarily in Asian countries as well as countries with a high numbers of diagnosed cases, Gilead said in a statement. The initiation of these studies follows the U.S. Food and Drug Administration's rapid review and acceptance of Gilead's investigational new drug filing for remdesivir. The new studies expand ongoing research into remdesivir, including trials in China and Japan and a NIH-sponsored study announced earlier this week that is the first in the U.S. Remdesivir, a broad-spectrum anti-viral drug, is not yet licensed or approved anywhere. Shares of Gilead ended the regular trading day up 6.6%.

US : U.S.: Nasdaq
$ 77.83
+2.51 +3.33%
Volume: 24.38M
May 29, 2020 4:00p
P/E Ratio
Dividend Yield
Market Cap
$97.60 billion
Rev. per Employee

Get news alerts on Gilead Sciences Inc. — or create your own.
This Story has 0 Comments
Be the first to comment
More News In

Story Conversation

Commenting FAQs »
Link to MarketWatch's Slice.